期刊
PHARMACEUTICAL RESEARCH
卷 30, 期 3, 页码 836-846出版社
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11095-012-0925-z
关键词
16S rRNA gene sequencing; F2 and C-K; ginseng; ginsenosides Rb1; microbiome; permeability; pharmacokinetic profile; rate-limiting step; Rd; stepwise metabolism
资金
- National Institutes of Health at University of Houston [AT-005522]
- National Institutes of Health at Medical College of Wisconsin
- National Institutes of Health at Hong Kong Baptist University
To investigate the ability of bacteria in the intestinal microbiome to convert naturally occurring primary ginsenosides in red ginseng extract to active secondary ginsenosides. Anti-proliferative ginsenoside activity was tested using mouse lung cancer LM1 cells. Permeabilities were evaluated in Caco-2 cell monolayers. Systemic exposure of secondary ginsenosides was determined in A/J mice. 16S rRNA gene pyrosequencing was used to determine membership and abundance of bacteria in intestinal microbiome. Secondary ginsenoside C-K exhibited higher anti-proliferative activity and permeability than primary ginsenosides. Significant amounts of secondary ginsenosides (F2 and C-K) were found in blood of A/J mice following oral administration of primary ginsenoside Rb1. Because mammalian cells did not hydrolyze ginsenoside, we determined the ability of bacteria to hydrolyze ginsenosides and found that Rb1 underwent stepwise hydrolysis to Rd, F2, and then C-K. Formation of F2 from Rd was the rate-limiting step in the biotransformation of Rb1 to C-K. Conversion to F2 is the rate-limiting step in bioactivation of primary ginsenosides by A/J mouse intestinal microbiome, whose characterization reveals the presence of certain bacterial families capable of enabling the formation of F2 and C-K in vivo.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据